HC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Astria Therapeutics ATXS and lower its price target from $20.00 to $18.00.

Shares of Astria Therapeutics are trading down 0.31% over the last 24 hours, at $6.40 per share.

A move to $18.00 would account for a 181.25% increase from the current share price.

About Astria Therapeutics

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.